Influence of Gene-Modified (IL-7, IL-4, and B7) Tumor Cell Vaccines on Tumor Antigen Presentation

Journal of Immunology

Volumn 158, Issue 6, 1997, Pages 2834-2841

  Cayeux, Sophie ^a,b   Richter, Günther ^b   Noffz, Gabriele ^b   Dörken, Bernd ^a,b   Blankenstein, Thomas ^b  

^a Section of Pathology   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; BETA GALACTOSIDASE; CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; H2 ANTIGEN; INTERLEUKIN 4; INTERLEUKIN 7; TUMOR ANTIGEN;

ADENOCARCINOMA; ANIMAL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; COLON TUMOR; CYTOTOXIC T LYMPHOCYTE; EXPERIMENTAL NEOPLASM; FEMALE; FIBROSARCOMA; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE; NUDE MOUSE;

ADENOCARCINOMA; ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD80; ANTIGENS, NEOPLASM; BETA-GALACTOSIDASE; CANCER VACCINES; COLONIC NEOPLASMS; FEMALE; FIBROSARCOMA; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; H-2 ANTIGENS; INTERLEUKIN-4; INTERLEUKIN-7; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0031569119     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Tepper, R. I., and J. J. Mule. 1994. Experimental and clinical studies of cytokine gene modified tumor cells. Hum. Gene Ther. 5:153.
2. Blankenstein, Th., S. Cayeux, and Z. Qin. 1996. Genetic approaches to cancer immunotherapy. Rev. Physiol. Biochem. Pharmacol. 129:1.
3. Blaese, M., Th. Blankenstein, M. Brenner, O. Cohen-Haguenauer, B. Gansbacher, B. Sorrentino, and T. Velu. 1995. Gene therapy for the medical oncologist. Eur. J. Cancer 31A:1531.
4. Hock, H., M. Dorsch, U. Kunzendorf, Z. Qin, T. Diamantstein, and T. Blankenstein. 1993. Mechanisms of rejection induced by tumor cell targeted gene transfer of interleukin-2, interleukin-4, interleukin-7, tumor necrosis factor or interferon-gamma. Proc. Natl. Acad. Sci. USA 90:2774.
5. Hock, H., M. Dorsch, U. Kunzendorf, K. Überla, Z. Qin, T. Diamantstein, and T. Blankenstein. 1993. Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res. 53:714.
6. Chen, L., S. Ashe, W. A. Brady, I. Hellström, K. E. Hellström, J. A. Ledbetter, P. McGowan, and P. S. Linsley. 1992. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093.
7. + T cells by B7-transfected melanoma cells. Science 259:368.
8. Cayeux, S., C. Beck, B. Dörken, and T. Blankenstein. 1996. Coexpression of interleukin 4 and B7.1 in murine tumor cells leads to improved tumor rejection and vaccine effect compared to single gene transfectants and a classical adjuvant. Hum. Gene Ther. 7:525.
9. Cayeux, S., C. Beck, A. Aicher, B. Dörken, and Th. Blankenstein. 1995. Tumor cells cotransfected with interleukin 7 and B7.1 genes induce CD25 and CD28 on tumor infiltrating lymphocytes and are strong vaccines. Eur. J. Immunol. 25: 2325.
10. Salvadori, S., B. Gansbacher, I. Wernick, S. Tirelli, and K. Zier. 1995. B7.1 amplifies the response to interleukin-2-secreting tumor vaccines in vivo, but fails to induce a response by naive cells in vitro. Hum. Gene Ther. 6:1299.
11. Coughlin, C. M., M. Wysocka, H. L. Kurzawa, W. M. F. Lee, G. Trinchieri, and S. L. Eck. 1995. B7.1 and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res. 55:4980.
12. Bevan, M. J. 1976. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med. 143:1283.
13. Huang, A. Y. C., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky. 1994. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961.
14. Huang, A. Y. C., A. T. Brace, D. Pardoll, and H. Levitsky. 1996. Does B7.1 expression confer antigen-presenting cell capacity to tumors in vivo? J. Exp. Med. 183:769.
15. Pulaski, B. A., K.-Y. Yeh, N. Shastri, K. M. Maltby, D. P. Penney, E. M. Lord, and J. G. Frelinger. 1996. Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex "re-presentation" of exogeneous antigen by tumor-infiltrating antigen-presenting cells. Proc. Natl. Acad. Sci. USA 93:3669.
16. + cytolytic T lymphocytes. J. Exp. Med. 183:791.
17. Gavin, M. A., M. J. Gilbert, S. R. Riddell, P. D. Greenberg, and M. J. Bevan. 1993. Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes. J. Immunol. 151:3971.
18. Oukka, M., M. Cohen-Tannoudji, Y. Tanaka, C. Babinet, and K. Kosmatopoulos. 1996. Medullary thymic epithelial cells induce tolerance to intracellular proteins. J. Immunol. 156:968.
19. Li, W., T. Diamantstein, and T. Blankenstein. 1990. Lack of tumorigenicity of interleukin 4 autocrine growing cells seems related to the anti-tumor function of interleukin 4. Mol. Immunol. 27:1331.
20. Laker, C., C. Stocking, U. Bergholz, N. Hess, J. F. De-Lamarter, and W. Ostertag. 1987. Autocrine stimulation after transfer of the granulocyte-macrophage-colony-stimulating-factor gene and autonomous growth are distinct but interdependent steps in the oncogenic pathway. Proc. Natl. Acad. Sci. USA 84:8458.
21. Park, L. S., D. J. Friend, A. E. Schmierer, S. K. Dower, and A. E. Namen. 1990. Murine interleukin 7 (IL-7) receptor: characterization on an IL-7-dependent cell line. J. Exp. Med. 171:1073.
22. Schwartz, R. H. 1992. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71: 1065.
23. Fearon, E. R., D. M. Pardoll, T. Itaya, P. Golumbek, H. I. Levitsky, J. W. Simons, H. Karasuyama, B. Vogelstein, and P. Frost. 1990. Interleukin 2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397.
24. Wu, L. C., A. Y. C. Huang, E. M. Jaffee, H. I. Levitsky, and D. M. Pardoll. 1995. A reassessment of the role of B7-1 expression in tumor rejection. J. Exp. Med. 182:1415.
25. + T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene transfection. J. Immunol. 149:3627.
26. Viola, A., and A. Lanzavecchia. 1996. T cell activation determined by T cell receptor number and tunable thresholds. Science 273:104.
27. Windhagen, A., J. Newcombe, F. Dangond, C. Strand, M. N. Woodroofe, M. L. Cuzner, and D. A. Hafler. 1995. Expression of costimulatory molecules B7.1 (CD80), B7.2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J. Exp. Med. 182:1985.
28. Grabbe, S., R. L. Gallo, A. Lindgren, and R. D. Granstein. 1993. Deficient antigen presentation by Langerhans cells from athymic (nu/nu) mice. J. Immunol. 151:3430.
29. Costello, R., H. Brailly, F. Mallet, C. Mawas, and D. Olive. 1993. Interleukin-7 is a potent co-stimulus of the adhesion pathway involving CD2 and CD28 molecules. Immunology 80:451.
30. Inaba, K., M. Inaba, M. Deguchi, K. Hagi, R. Yasumizu, S. Ikehara, and S. Muramatsu. 1993. Granulocytes, macrophages, and dendritic cells arise from a common major histocompalibility complex class II-negative progenitor in mouse bone marrow. Proc. Natl. Acad. Sci. USA 90:3038.
31. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad Sci. USA 90:3539.
32. Townsend, S. E., F. W. Su, J. M. Atherton, and J. P. Allison. 1994. Specificity and longetivity of antitumor immune responses induced by B7-transfected tumors. Cancer Res. 54:6477.
33. Allione, A., M. Consalvo, P. Nanni, P. L. Lollini, F. Cavallo, M. Giovarelli, M. Forni, A. Gulino, M. P. Colombo, P. Dellabona, H. Hock, Th. Blankenstein, F. M. Rosenthal, B. Gansbacher, M. C. Bosco, T. Musso, L. Gusella, and G. Forni. 1994. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor α, granulocyte-macrophage colony-stimulating factor, and γ-interferon gene or admixed with conventional adjuvants. Cancer Res. 54:6022.